{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-037205","form_type":"8-K","ticker":"OPRX","cik":"0001448431","company_name":"OptimizeRx Corp","filed_at":"2024-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.464020+00:00","generated_at":"2026-06-03T05:29:17.482113+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"OptimizeRx prelim Q1 revenue $18.5-19.2M (+40% YoY); ahead of consensus","bullets":["Revenue expected between $18.5M and $19.2M for Q1 2024, over 40% growth YoY; GAAP net loss $(8.2)-$(7.0)M.","Adjusted EBITDA loss of $(1.0)-$(0.7)M; results driven by DAAP platform and October 2023 Medicx acquisition.","Signed 9 new Dynamic Audience Activation Platform (DAAP) deals in Q1; cross-selling ahead of internal expectations.","Medicx integration ahead of schedule; management estimates $2.8B potential opportunity from existing brands alone.","Earnings call scheduled for May 14, 2024 at 4:30 p.m. ET to discuss full Q1 results."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-037205","json":"https://secwatch.observer/filing/0001213900-24-037205.json","markdown":"https://secwatch.observer/filing/0001213900-24-037205.md","text":"https://secwatch.observer/filing/0001213900-24-037205.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1448431/000121390024037205/0001213900-24-037205-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1448431/000121390024037205/ea0204901-8k_optimizer.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T05:29:17.482113+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c1d2f9db4e93364d3f80bd6b2e402e81d8e45d29","claim":"OptimizeRx Corp reported first quarter for the period ended March 31, 2024 results: revenue between $18.5 million and $19.2 million.","evidence_excerpt":"the Company expects revenue to increase over 40% year-over-year and come in between $18.5 million and $19.2 million with a GAAP net loss and Adjusted EBITDA loss between $(8.2) - $(7.0) million and $(1.0) - $(0.7) million, respectively","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1448431/000121390024037205/0001213900-24-037205-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter for the period ended March 31, 2024"},{"label":"Revenue","value":"between $18.5 million and $19.2 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}